NASDAQ:ELGX - Endologix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $6.85 -0.10 (-1.44 %) (As of 05/21/2019 04:42 AM ET)Previous Close$6.95Today's Range$6.58 - $7.0052-Week Range$5.20 - $67.20Volume346,900 shsAverage Volume195,670 shsMarket Capitalization$114.99 millionP/E RatioN/ADividend YieldN/ABeta0.58 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California. Receive ELGX News and Ratings via Email Sign-up to receive the latest news and ratings for ELGX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ELGX Previous Symbol CUSIP29266S10 CIK1013606 Webwww.endologix.com Phone949-595-7200Debt Debt-to-Equity Ratio11.12 Current Ratio1.58 Quick Ratio0.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$156.47 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value$1.15 per share Price / Book5.96Profitability EPS (Most Recent Fiscal Year)($7.20) Net Income$-79,710,000.00 Net Margins-54.72% Return on Equity-173.52% Return on Assets-19.80%Miscellaneous Employees528 Outstanding Shares16,787,000Market Cap$114.99 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Endologix (NASDAQ:ELGX) Frequently Asked Questions What is Endologix's stock symbol? Endologix trades on the NASDAQ under the ticker symbol "ELGX." When did Endologix's stock split? How did Endologix's stock split work? Shares of Endologix reverse split on Wednesday, March 6th 2019. The 1-10 reverse split was announced on Tuesday, March 5th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 5th 2019. An investor that had 100 shares of Endologix stock prior to the reverse split would have 10 shares after the split. How were Endologix's earnings last quarter? Endologix, Inc. (NASDAQ:ELGX) issued its quarterly earnings data on Thursday, May, 2nd. The medical instruments supplier reported ($1.12) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.56) by $0.44. The medical instruments supplier earned $35.61 million during the quarter, compared to the consensus estimate of $34.18 million. Endologix had a negative net margin of 54.72% and a negative return on equity of 173.52%. View Endologix's Earnings History. When is Endologix's next earnings date? Endologix is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Endologix. What guidance has Endologix issued on next quarter's earnings? Endologix issued an update on its first quarter 2019 earnings guidance on Monday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $35-35 million, compared to the consensus revenue estimate of $32.67 million.Endologix also updated its FY 2019 guidance to EPS. What price target have analysts set for ELGX? 5 brokers have issued 12-month price objectives for Endologix's shares. Their predictions range from $7.00 to $40.00. On average, they anticipate Endologix's share price to reach $29.40 in the next twelve months. This suggests a possible upside of 329.2% from the stock's current price. View Analyst Price Targets for Endologix. What is the consensus analysts' recommendation for Endologix? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endologix in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endologix. What are Wall Street analysts saying about Endologix stock? Here are some recent quotes from research analysts about Endologix stock: 1. According to Zacks Investment Research, "Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis. " (4/16/2019) 2. BTIG Research analysts commented, ": We reiterate our Overweight rating and are lowering our 12-month price target to $85/share from $86/share on AERI. Aerie Pharmaceuticals reported earnings and hosted a conference call to discuss financial and corporate updates for 4Q18/2018. The quarter produced strong Rhopressa sales of $14.5 million. Our focus in 2019 will be on a potential Rocklatan approval, company guidance for revenue projections, and the international expansion of Aerie’s glaucoma drugs to further penetrate the market potential." (2/26/2019) Has Endologix been receiving favorable news coverage? Media stories about ELGX stock have been trending somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Endologix earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Endologix's key competitors? Some companies that are related to Endologix include Antares Pharma (ATRS), Valeritas (VLRX), SI-Bone (SIBN), GenMark Diagnostics (GNMK), MiMedx Group (MDXG), Accuray (ARAY), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Westaim (WEDXF), Vapotherm (VAPO), Neuronetics (STIM), SeaSpine (SPNE), Pulse Biosciences (PLSE), Iradimed (IRMD) and Cytosorbents (CTSO). What other stocks do shareholders of Endologix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Endologix investors own include CA (CA), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Och-Ziff Capital Management Group (OZM), Gran Tierra Energy (GTE), Precision Drilling (PD) and Belden (BDC). Who are Endologix's key executives? Endologix's management team includes the folowing people: Mr. John Onopchenko, CEO & Director (Age 60)Mr. Vaseem Mahboob, Chief Financial Officer (Age 50)Dr. Michael V. Chobotov, Chief Technology Officer (Age 58)Mr. Jeffrey S. Brown, Chief Operations OfficerMr. Jeremy B. Hayden, Gen. Counsel (Age 49) Who are Endologix's major shareholders? Endologix's stock is owned by a number of of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (10.03%), BlackRock Inc. (5.90%), NEA Management Company LLC (2.41%), Stephens Inc. AR (2.31%), New York State Common Retirement Fund (1.55%) and Altrinsic Global Advisors LLC (1.26%). Company insiders that own Endologix stock include Christopher G Chavez, Dan Lemaitre, John Onopchenko, Thomas F Zenty III, Thomas Wilder and Vaseem Mahboob. View Institutional Ownership Trends for Endologix. Which institutional investors are selling Endologix stock? ELGX stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, BlackRock Inc., NEA Management Company LLC, Stephens Inc. AR, New York State Common Retirement Fund, Northern Trust Corp, Altrinsic Global Advisors LLC and JPMorgan Chase & Co.. Company insiders that have sold Endologix company stock in the last year include Christopher G Chavez and Thomas Wilder. View Insider Buying and Selling for Endologix. Which institutional investors are buying Endologix stock? ELGX stock was purchased by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Trexquant Investment LP and Acadian Asset Management LLC. Company insiders that have bought Endologix stock in the last two years include Dan Lemaitre, John Onopchenko, Thomas F Zenty III and Vaseem Mahboob. View Insider Buying and Selling for Endologix. How do I buy shares of Endologix? Shares of ELGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Endologix's stock price today? One share of ELGX stock can currently be purchased for approximately $6.85. How big of a company is Endologix? Endologix has a market capitalization of $114.99 million and generates $156.47 million in revenue each year. The medical instruments supplier earns $-79,710,000.00 in net income (profit) each year or ($7.20) on an earnings per share basis. Endologix employs 528 workers across the globe. What is Endologix's official website? The official website for Endologix is http://www.endologix.com. How can I contact Endologix? Endologix's mailing address is 2 MUSICK, IRVINE CA, 92618. The medical instruments supplier can be reached via phone at 949-595-7200 or via email at [email protected] MarketBeat Community Rating for Endologix (NASDAQ ELGX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 400 (Vote Outperform)Underperform Votes: 395 (Vote Underperform)Total Votes: 795MarketBeat's community ratings are surveys of what our community members think about Endologix and other stocks. Vote "Outperform" if you believe ELGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELGX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Federal Reserve Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.